Sacramento, United States
one.bio, founded in 2019, is an innovative biotechnology spinout from UC Davis that harnesses proprietary technology to create novel oligosaccharides from natural products. Specializing in the biotechnology, food and beverage, and healthcare industries, the company emphasizes producing ingredients that beneficially modulate the microbiome and immune function.
With its headquarters in the United States, one.bio aims to carve out a niche in producing novel prebiotics, synbiotics, and immuno-modulatory therapies. The company's slogan, "Creating novel prebiotics, synbiotics and immuno-modulatory therapies from the untapped world of natural carbohydrates," succinctly encapsulates its vision.
In its mission to innovate within the sector, one.bio secured a $12.00M Series A investment on April 13, 2022. This funding round was led by prominent investors such as Seventure Partners, Acre Venture Partners, Collaborative Fund, iSelect, and Skyviews Life Science, indicating strong market confidence in its potential to disrupt the industry.
Epinoma